Answers are grounded in this paper and cite their sources.
Case report demonstrates marked improvement in chronic hand eczema with delgocitinib in a young patient, highlighting its role as second-line therapy.
This case describes a young patient presenting with severe chronic hand eczema despite topical corticosteroid treatment with a preference for non-systemic treatment. She has a Dermatology Life Quality Index score of 12. She has marked clinical improvement after eight months of topical delgocitinib treatment, demonstrating the emerging role of topical pan-Janus kinase inhibitors as second-line therapy.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: